Hallucinations
17
1
1
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (17)
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
Pain Medicine for Wound Care Procedures
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
HD-tDCS for Hallucinations
Impact of Closely Grouped, Iterative Exposures to Suxamethonium During ECT on the Sensitization to NMBA and the Development of Protective Antibodies
Cognitive Behaviour Therapy for Voices and Dissociation
Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations
Transcranial Magnetic Stimulation for "Voices"
Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis
ReMindCare App for Patients From First Episode of Psychosis Unit.
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
Understanding Hallucinations (Part II)
Understanding Hallucinations (Part I)
Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations
Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug